• In recent days, IDEX reported slowing organic revenue growth over the last two years, alongside weaker-than-hoped earnings per share and a reduced return on invested capital, pointing to softer demand in its core operations.
• This combination of cooling top-line momentum and declining capital efficiency raises questions about how many high-quality growth opportunities remain within IDEX’s portfolio.
• We’ll now examine how the slowdown in IDEX’s organic revenue growth could influence the company’s previously optimistic investment narrative and outlook.

Find 49 companies with promising cash flow potential yet trading below their fair value.

IDEX Investment Narrative Recap

To own IDEX, you really need to believe its niche industrial solutions can keep earning solid returns on capital, even when demand cools. The recent slowdown in organic revenue and weaker EPS makes the key short term catalyst more execution driven: proving that cost savings, integration efforts and pricing can offset softer volumes. The biggest risk right now is that lower organic growth and declining ROIC signal a thinner pipeline of truly attractive projects, rather than a temporary pause.

Against this backdrop, the ongoing share repurchase program, which has retired roughly a quarter of the share count for about US$1,682.6 million, is one of the more relevant developments. While buybacks can support per share metrics in the near term, they also put more focus on how effectively IDEX converts its existing project portfolio into resilient organic growth, especially as some end markets, such as semiconductor and agriculture, have already shown signs of softer demand.

But investors also need to be aware that if organic growth keeps fading while ROIC drifts lower, then ...

IDEX's narrative projects $4.2 billion revenue and $697.3 million earnings by 2029. This requires 5.6% yearly revenue growth and about a $189.6 million earnings increase from $507.7 million today.

Uncover how IDEX's forecasts yield a $238.29 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently see IDEX’s fair value between about US$180 and US$287.78, underlining how far apart views can be. Set that against the recent slowdown in organic growth and ROIC, and you have a useful reminder to compare multiple opinions before deciding what the company’s long term earnings power might look like.

Explore 3 other fair value estimates on IDEX - why the stock might be worth as much as 26% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your IDEX research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free IDEX research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEX's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.